Bayer

New drug applications for Bayer’s FXIa inhibitor accepted by U.S. Food and Drug Administration under Priority Review and by Japan’s Ministry of Health, Labour and Welfare

19 May 2026

FDA grants sevabertinib Priority Review as a first-line treatment for patients with HER2-mutant non-small cell lung cancer

18 May 2026

Bayer AG First Quarter 2026 Results and Media Update

12 May 2026

Bayer reports solid start to the year and confirms currency-adjusted Group guidance for 2026

12 May 2026

AskBio Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting

08 May 2026

China’s Center of Drug Evaluation grants Priority Review designation for Bayer’s FXIa inhibitor

08 May 2026

Investigational PET Tracer from Bayer Met Primary Endpoints in Phase III Study

08 May 2026

Bayer and bp form strategic alliance to jointly scale camelina as intermediate crop for biofuels

08 May 2026

Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline

08 May 2026

China’s Center of Drug Evaluation accepts marketing authorization application for asundexian in stroke prevention after a non-cardioembolic ischemic stroke or transient ischemic attack

29 Apr 2026

View details about the software product Informachine News Trackers